NVIDIA cuDSS Now Generally Available to Accelerate Engineering and Scientific Simulations
NVIDIA cuDSS, a CUDA-X library, is now generally available. It shifts a critical part of engineering and scientific simulations onto GPUs, enabling applications to reduce time to results and increase simulation throughput. Industry leaders such as Applied Materials, COMSOL, Cadence, Dassault Systèmes, Siemens, and Synopsys are already integrating cuDSS into their tools, with some reporting speedups of up to 10x.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
24H Trending
-
1
U.S. Secretary of State Rubio visited India's Reliance refinery to discuss increasing the refining of Venezuelan crude oil, aiming to balance sanctions against Russia with oil price stability.
-
2
Iran Denies Imminent Economic Collapse, US Says Revolutionary Guard Faces Funding Shortages
-
3
Oracle, Meta, and SpaceX credit default swaps (CDS) hit all-time highs, as the market anticipates a surge in AI-related bond issuance in Q4.
-
4
CME Group announced that FalconX and GSR completed the first block trades of its newly launched Bitcoin Cash and Uniswap futures on October 20.
-
5
SEC and Japan's FSA Held Autumn Financial Regulatory Dialogue in Tokyo on Oct. 19
-
6
Ontario International Airport plans to issue approximately $174 million in municipal bonds to finance several improvement projects.
-
7
Tx launches Brale-issued USTX stablecoin, mintable with USDC from eight networks, to pull RWA liquidity onto its chain for settling tokenized stocks and other assets.
-
8
Microsoft, Alphabet, Goldman Sachs among seven more companies objecting to OKX-ICE tokenized stock trading, bringing total to 16
-
9
Bloomberg columnist Jonathan Levin wrote that CoreWeave bonds plunged this month, with yields on notes due in 2032 briefly soaring to 15%, sounding an alarm for the corporate credit market. The Federal Reserve should hold steady at its October policy meeting.
-
10
Novo Nordisk's next-generation obesity drug CagriSema showed an average weight reduction of 25% in women in a late-stage analysis.
Markets Today
Recommended Reading


